244.32
price down icon0.34%   -0.84
after-market Handel nachbörslich: 244.32
loading
Schlusskurs vom Vortag:
$245.16
Offen:
$239.25
24-Stunden-Volumen:
353.16K
Relative Volume:
0.83
Marktkapitalisierung:
$28.51B
Einnahmen:
$3.81B
Nettoeinkommen (Verlust:
$-644.79M
KGV:
-39.15
EPS:
-6.24
Netto-Cashflow:
$-669.77M
1W Leistung:
-8.54%
1M Leistung:
-0.65%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$239.25
$244.65
1-Wochen-Bereich:
Value
$239.25
$266.32
52-Wochen-Spanne:
Value
$172.67
$287.88

Beone Medicines Ltd Adr Stock (ONC) Company Profile

Name
Firmenname
Beone Medicines Ltd Adr
Name
Telefon
13459494123
Name
Adresse
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Name
Mitarbeiter
11,000
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
ONC's Discussions on Twitter

Vergleichen Sie ONC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33

Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-07 Eingeleitet RBC Capital Mkts Outperform
2025-03-03 Hochstufung BofA Securities Neutral → Buy
2024-12-03 Fortgesetzt Morgan Stanley Overweight
2024-09-18 Eingeleitet JMP Securities Mkt Outperform
2024-02-06 Fortgesetzt JP Morgan Overweight
2023-09-12 Eingeleitet Macquarie Outperform
2023-08-17 Eingeleitet Jefferies Buy
2023-07-17 Eingeleitet Citigroup Buy
2023-06-30 Herabstufung Bernstein Outperform → Mkt Perform
2023-01-12 Eingeleitet Daiwa Securities Buy
2022-10-13 Hochstufung Guggenheim Neutral → Buy
2022-10-13 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-08-09 Fortgesetzt JP Morgan Overweight
2022-03-17 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-02-07 Eingeleitet Deutsche Bank Buy
2021-10-12 Eingeleitet Bernstein Outperform
2021-10-06 Hochstufung CLSA Underperform → Buy
2021-03-08 Eingeleitet China Renaissance Buy
2021-03-01 Herabstufung CLSA Outperform → Underperform
2020-11-09 Herabstufung Ladenburg Thalmann Buy → Neutral
2020-11-06 Herabstufung Maxim Group Buy → Hold
2020-11-06 Herabstufung Piper Sandler Neutral → Underweight
Alle ansehen

Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten

pulisher
Jun 18, 2025

Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) COO Sells 1,543 Shares of Stock - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Insider Sells $118,143.90 in Stock - MarketBeat

Jun 18, 2025
pulisher
Jun 17, 2025

BeOne Medicines (NASDAQ:ONC) Stock Price Down 5.4%Here's What Happened - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat

Jun 16, 2025
pulisher
Jun 13, 2025

Entergy Corp’s Shares Reel: 0.54% Quarterly Revenue Decline Amid 35.88B Market Cap - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

BeOne Medicines Ltd ADR (ONC) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jun 13, 2025
pulisher
Jun 05, 2025

Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily

Jun 05, 2025
pulisher
Jun 03, 2025

LLY Stock Quote Price and Forecast - CNN

Jun 03, 2025
pulisher
Jun 02, 2025

H.C. Wainwright maintains neutral rating on Zymeworks stock - Investing.com India

Jun 02, 2025
pulisher
May 31, 2025

China approves novel HER2-targeted therapy for BTC By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge By Stocktwits - Investing.com India

May 30, 2025
pulisher
May 30, 2025

China approves novel HER2-targeted therapy for BTC - Investing.com Australia

May 30, 2025
pulisher
May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.

May 30, 2025
pulisher
May 27, 2025

BeiGene completes corporate re-domiciliation to Switzerland - Investing.com

May 27, 2025
pulisher
May 27, 2025

BeiGene completes corporate re-domiciliation to Switzerland By Investing.com - Investing.com Nigeria

May 27, 2025
pulisher
May 26, 2025

Daiwa Raises BEIGENE's TP to HKD180; Brukinsa Sales Growth Outpaces Competitors - AASTOCKS.com

May 26, 2025
pulisher
May 21, 2025

BeiGene Shareholders Approve Director Elections and Auditors By Investing.com - Investing.com India

May 21, 2025
pulisher
May 13, 2025

Daiwa Sees Limited Upside for HSI, Prefers HK Stocks w/ Tech Trading Opportunities Like BEIGENE - AASTOCKS.com

May 13, 2025
pulisher
May 08, 2025

Market Momentum: BeiGene Ltd. ADR (ONC) Registers a -3.93 Decrease, Closing at 232.25 - DWinneX

May 08, 2025
pulisher
May 07, 2025

BeiGene shares tumble over 5% as Q1 revenue misses estimates - Investing.com

May 07, 2025
pulisher
May 07, 2025

BeiGene shares tumble over 5% as Q1 revenue misses estimates By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
Apr 29, 2025

BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

BeiGene wins patent challenge against Pharmacyclics - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

BeiGene wins US patent dispute over cancer drug By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 29, 2025

Universal Health Q1 Earnings Beat on Strong Acute Care Admissions - Zacks Investment Research

Apr 29, 2025
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa

Apr 28, 2025
pulisher
Apr 28, 2025

BeiGene reports financial results under PRC GAAP - Investing.com

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance

Apr 24, 2025
pulisher
Apr 21, 2025

BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com

Apr 21, 2025
pulisher
Apr 21, 2025

RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com

Apr 21, 2025
pulisher
Apr 17, 2025

BGNE Page Not Found - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India

Apr 16, 2025
pulisher
Apr 16, 2025

Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 10, 2025

Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com

Apr 10, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com

Apr 07, 2025
pulisher
Apr 04, 2025

JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

BeiGene stock slips on trial discontinuation (ONC:NASDAQ) - Seeking Alpha

Apr 03, 2025
pulisher
Mar 31, 2025

Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com

Mar 31, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India

Mar 20, 2025
pulisher
Mar 18, 2025

Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com

Mar 18, 2025

Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Beone Medicines Ltd Adr-Aktie (ONC) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Wu Xiaobin
President and COO
Jun 23 '25
Sale
260.00
1,363
354,380
0
Wang Xiaodong
Chair, Scientific Advisory Brd
Jun 24 '25
Sale
265.50
2,007
532,867
0
OYLER JOHN
Chief Executive Officer
Jun 23 '25
Sale
261.61
3,174
830,360
0
$108.26
price up icon 0.70%
$545.11
price up icon 0.49%
$329.77
price up icon 2.39%
$98.24
price up icon 0.64%
$22.62
price up icon 6.70%
Kapitalisierung:     |  Volumen (24h):